# US 5,350,753 A · Pharmaceutical combination preparations containing cephalosporin and xanthine derivatives and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,350,753 A
- Document ID: US5350753A
- Status: Granted
- Kind: A
- Application number: 07/717,330
- Filed: 1991-06-18
- Granted: 1994-09-27
- Earliest claimed: 1990-06-20
- Assignees: Hoechst Aktiengesellschaft
- Inventors: Norbert Klesel; Michael Limbert; Elmar Schrinner
- Web page: https://patentgrep.com/patent/US5350753A

## CPC

- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Pharmaceutical combination preparations containing cefotaxime and at least one xanthine derivative are suitable for the treatment of bacterial infectious diseases and for the treatment of septic shock.

## Claims

### Claim 1

A composition containing an effective amount of cefotaxime and at least one xanthine derivative selected from the group consisting of
1-(5-hydroxyhexyl)-3-methyl-7-propylxanthine,
3-methyl-1-(5-oxohexyl)-7-propylxanthine,
7-propyl-1-(5-hydroxy-5-methylhexyl)-3-methylxanthine,
7-ethoxymethyl-1-(5-hydroxy-5-methylhexyl)-3-methylxanthine, 3-methyl-l-(5-oxohexyl)-7-(2-oxopropyl)-xanthine and
1-(5-hydroxy-5-methylhexyl)-3-methylxanthine.

### Claim 2 (depends on 1)

The composition as claimed in claim 1, wherein the xanthine derivative is 1-(5-hydroxy-5-methylhexyl)-3methylxanthine.

### Claim 3 (depends on 1)

The composition as claimed in claim 1, which contains cefotaxime and 1-(5-hydroxy-5-methylhexyl )-3methylxanthine.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the composition as claimed in claim 1 and a pharmaceutically suitable carrier.

### Claim 5

(Amended) A method for treatment of bacterial infectious diseases comprising administering to a host in need thereof an effective amount of cefotaxime and at least one xanthine derivative selected from the group consisting of
1-(5-hydroxyhexyl)-3-methyl-7-propylxanthine,
3-methyl-1-(5-oxohexyl)-7-propylxanthine,
7-propyl-1-(5-hydroxy-5-methylhexyl)-3-methylxanthine,
7-ethoxymethyl-1-(5-hydroxy-5-methylhexyl)-3-methylxanthine,
3-methyl-1-(5-oxohexyl)-7-(2-oxopropyl)-xanthine and
1-(5-hydroxy-5-methylhexyl)-3-methylxanthine.

### Claim 6

A method for treatment of septic shock comprising administering to a host in need thereof an effective amount of cefotaxime and at least one xanthine derivative selected from the group consisting of
1-(5-hydroxyhexyl)-3-methyl-7-propylxanthine,
3-methyl-1-(5-oxohexyl)-7-propylxanthine,
7-propyl-1-(5-hydroxy-5-methylhexyl)-3-methylxanthine,
7-ethoxymethyl-1-(5-hydroxy-5-methylhexyl)-3-methylxanthine,
3-methyl-1-(5-oxohexyl)-7-(2-oxopropyl)-xanthine and
1-(5-hydroxy-5-methylhexyl)-3-methylxanthine.